Global Human Immune Globulin Intravenous Market Size By Type (IVIg Liquid, IVIg Powder), By Application (Immunodeficiency, Autoimmune Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Immune Globulin Intravenous (IVIG) Market was valued at USD 13.2 billion in 2023 and is projected to reach USD 21.6 billion by 2031, growing at a CAGR of 6.4% during the forecast period (2023–2031). This market is expanding steadily due to the increasing prevalence of immunodeficiency disorders, rising geriatric population, and growing use of IVIG therapy in treating autoimmune and inflammatory diseases. Additionally, advancements in plasma fractionation technology and improved healthcare infrastructure globally are further accelerating market growth.

Drivers:

1. Growing Prevalence of Immunodeficiency and Autoimmune Disorders

Diseases such as primary immunodeficiency disease (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, and myasthenia gravis are increasingly being treated with IVIG. Rising awareness and diagnosis of these conditions significantly drive demand.

2. Expanding Geriatric Population

Elderly individuals are more susceptible to immune-related conditions and chronic inflammatory disorders, which increases the need for immunoglobulin therapies globally.

3. Technological Advancements in Plasma Collection and Processing

Enhanced plasma fractionation techniques and improved logistics in plasma supply are supporting a steady and safe supply of IVIG products, fueling the market.

Restraints:

1. High Cost of Therapy

IVIG therapy is expensive due to the complex plasma extraction process and limited donor availability. These high treatment costs can hinder widespread access, especially in low- and middle-income countries.

2. Risk of Adverse Effects and Supply Constraints

Potential adverse reactions, such as thromboembolism and hemolysis, along with dependency on human plasma donors, present limitations in scalability and consistent supply.

Opportunity:

1. Increasing Research for New Indications

Ongoing clinical research exploring the use of IVIG in treating neurological and dermatological conditions presents significant growth opportunities.

2. Market Penetration in Emerging Economies

Rapidly developing healthcare systems in regions like Asia-Pacific and Latin America are creating favorable conditions for IVIG market expansion through improved diagnosis rates and availability of specialty therapies.

Market by System Type Insights:

The Polyclonal IVIG segment dominates the market, driven by its widespread application in immune system support for both primary and secondary immunodeficiencies. Polyclonal IVIG remains the preferred formulation due to its broader spectrum of antibodies, offering superior clinical outcomes in various conditions. Meanwhile, Monoclonal IVIG formulations are gaining traction for targeted applications in autoimmune and neurological disorders.

Market by End-use Insights:

Hospitals emerged as the leading end-use segment in 2023, accounting for over 60% of global revenue. The critical care settings required for IVIG administration make hospitals the primary avenue for treatment delivery. In addition, the Homecare segment is anticipated to witness the fastest growth, driven by rising patient preference for convenience and cost-effective treatment alternatives, supported by innovations in infusion technology.

Market by Regional Insights:

North America held the largest market share in 2023, attributed to well-established healthcare infrastructure, high awareness levels, and the presence of leading market players. Asia-Pacific, however, is forecast to register the highest growth rate during the forecast period due to increasing healthcare investments, rising prevalence of immune disorders, and growing accessibility to advanced treatments in countries such as China, India, and South Korea.

Competitive Scenario:

Prominent companies in the Global Human Immune Globulin Intravenous Market include:

CSL Behring

Grifols S.A.

Takeda Pharmaceutical Company Limited

Octapharma AG

Kedrion Biopharma Inc.

ADMA Biologics

Bio Products Laboratory Ltd.

China Biologic Products Holdings, Inc.

Green Cross Corporation

These firms focus on expanding plasma collection networks, investing in R&D for novel formulations, and enhancing global distribution networks.

Scope of Work – Global Human Immune Globulin Intravenous Market

Key Market Developments:

2023: Grifols launched its next-generation IVIG formulation designed to reduce infusion time and side effects, enhancing patient comfort.

2024: CSL Behring announced the opening of new plasma collection centers across the U.S. to meet growing IVIG demand.

2025: Takeda received regulatory approval in Japan for subcutaneous immunoglobulin therapy, expanding its global immunology portfolio.

FAQs:

1) What is the current market size of the Global Human Immune Globulin Intravenous Market?

The market was valued at USD 13.2 billion in 2023.

2) What is the major growth driver of the Global Human Immune Globulin Intravenous Market?

The key growth driver is the rising prevalence of autoimmune and immunodeficiency disorders.

3) Which is the largest region during the forecast period in the Global Human Immune Globulin Intravenous Market?

North America is the largest region, owing to advanced healthcare systems and high diagnosis rates.

4) Which segment accounted for the largest market share in the Global Human Immune Globulin Intravenous Market?

The Polyclonal IVIG segment held the largest share in 2023.

5) Who are the key market players in the Global Human Immune Globulin Intravenous Market?

Major players include CSL Behring, Grifols S.A., Takeda, Octapharma, and Kedrion Biopharma.